A 7M-parameter AI model from a Samsung researcher, TRM, outperforms giants like Google's Gemini on complex reasoning tasks, challenging the industry's focus on scale.
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...
Recursion Pharmaceuticals jumped by 16.44 percent on Wednesday to close at $6.09 apiece as investors repositioned portfolios ahead of expected updates from an upcoming AI conference in Dubai.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback